Autopsy report · NCT00060801
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
Cause of deathNo reason given
Life of this trial
- 420 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Cystic Fibrosis
- Interventions
- BIIL 283 BS (Amelubent)
- Participants
- 420
- Sites
- 35
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.